Senti Biosciences, Inc. (NASDAQ: SNTI) announced it has completed enrollment in its Phase 1 clinical trial evaluating SENTI-202 for patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE